Skip to content

INVESTORS & MEDIA

MSParis2017 Congress, the 7th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Oct 25–28, 2017

Additional Information

Atara’s collaborating investigators will present results from two studies during the upcoming MSParis 2017 Congress. Updated, interim results will be presented from a Phase 1 study of an autologous version of ATA188, an Epstein-Barr Virus (EBV) specific T-cell immunotherapy, conducted by the Company’s collaborating investigators at the QIMR Berghofer Medical Research Institute and The University of Queensland.  The meeting will also feature new results by Atara and its collaborating investigators at Stanford Medicine characterizing the molecular signature of EBV in MS brain lesions. The MSParis2017 Congress will be held October 25-28, 2017, at the Palais des Congrès de Paris, in Paris, France. Details for the poster presentations are as follows:

Abstract Title: Safety and clinical improvement in a phase 1 trial of autologous Epstein-Barr virus-specific T cell therapy in patients with progressive multiple sclerosis

Session Title: Poster Session 1
Presentation Date & Time: Thursday, October 26, 2017; 15:30 CEST
Lead Authors: Michael Pender, M.D., and Professor Rajiv Khanna

Abstract Title: Molecular signature of Epstein-Barr virus infection in multiple sclerosis brain lesions

Session Title: Poster Session 2
Presentation Date & Time: Friday, October 27, 2017; 15:30 CEST
Lead Authors: May Han, M.D., and Lawrence Steinman, M.D.

View Press Release


Remind Me


MSParis2017 Congress, the 7th Joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Remind Me

Please sign up for Email alerts.